Diamyd Medical AB (publ)
SSE:DMYD-B.ST
13.3 (SEK) • At close February 20, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) SEK.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0.13 | 0.546 | 0.454 | 0.253 | 0.341 | 1.568 | 0.726 | 0.922 | 0.757 | 0.513 | 0.443 | 0.1 | 1.078 | 280.752 | 113.028 |
| Cost of Revenue
| 3.71 | 3.634 | 4.403 | 2.501 | 4.488 | 1.693 | 2.109 | 1.74 | 0.911 | 1.351 | 1.262 | 0.756 | 0 | 0.007 | 0.026 |
| Gross Profit
| -3.58 | -3.088 | -3.949 | -2.248 | -4.147 | -0.125 | -1.383 | -0.818 | -0.154 | -0.838 | -0.819 | -0.656 | 1.078 | 280.745 | 113.002 |
| Gross Profit Ratio
| -27.538 | -5.656 | -8.698 | -8.885 | -12.161 | -0.08 | -1.905 | -0.887 | -0.203 | -1.634 | -1.849 | -6.56 | 1 | 1 | 1 |
| Reseach & Development Expenses
| 96.484 | 69.909 | 75.567 | 56.86 | 13.81 | 22.359 | 29.118 | 12.871 | 6.22 | 9.686 | 5.465 | 3.519 | 25.048 | 95.976 | 80.845 |
| General & Administrative Expenses
| 0 | 0 | 11.669 | 9.457 | 6.858 | 6.017 | 5.408 | 4.658 | 4.514 | 4.105 | 3.614 | 3.433 | 12.708 | 15.762 | 19.095 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 44.787 | 39.695 | 11.669 | 9.457 | 6.858 | 6.017 | 5.408 | 4.658 | 4.514 | 4.105 | 3.614 | 3.433 | 12.708 | 15.762 | 19.095 |
| Other Expenses
| 1.716 | 42.849 | 23.751 | 17.316 | -34.555 | 8.067 | 8.128 | 7.174 | 21.171 | 6.939 | 6.834 | 5.424 | 26.747 | 0.41 | 0.41 |
| Operating Expenses
| 142.987 | 112.758 | 110.987 | 83.633 | -13.887 | 36.443 | 42.654 | 24.703 | 31.905 | 20.73 | 15.913 | 12.376 | 64.503 | 169.406 | 115.965 |
| Operating Income
| -146.567 | -120.806 | -118.176 | -85.88 | 9.739 | -36.569 | -44.036 | -25.52 | -32.059 | -21.568 | -16.732 | -13.032 | -63.425 | 111.339 | -2.963 |
| Operating Income Ratio
| -1,127.438 | -221.256 | -260.3 | -339.447 | 28.56 | -23.322 | -60.656 | -27.679 | -42.35 | -42.043 | -37.77 | -130.32 | -58.836 | 0.397 | -0.026 |
| Total Other Income Expenses Net
| -5.283 | 4.732 | 14.66 | 145.926 | -0.03 | -0.041 | 0.084 | -0.034 | 0.051 | 0.171 | 0.698 | 0.399 | 11.91 | -9.496 | 2.687 |
| Income Before Tax
| -151.85 | -116.074 | -103.516 | 60.046 | 9.709 | -36.61 | -43.953 | -25.555 | -32.008 | -21.397 | -16.034 | -12.633 | -51.515 | 101.843 | -0.276 |
| Income Before Tax Ratio
| -1,168.077 | -212.59 | -228.009 | 237.336 | 28.472 | -23.348 | -60.541 | -27.717 | -42.283 | -41.71 | -36.194 | -126.33 | -47.788 | 0.363 | -0.002 |
| Income Tax Expense
| -6.105 | 4.734 | -14.659 | -143.961 | 0.53 | 0.121 | 0.286 | 0.033 | 13.543 | 0 | 0 | 0 | 0.16 | -0.727 | 0.056 |
| Net Income
| -151.85 | -116.073 | -88.857 | 204.007 | 9.709 | -36.731 | -43.953 | -25.555 | -32.008 | -21.397 | -16.034 | -12.633 | -51.675 | 102.57 | -0.332 |
| Net Income Ratio
| -1,168.077 | -212.588 | -195.72 | 806.352 | 28.472 | -23.425 | -60.541 | -27.717 | -42.283 | -41.71 | -36.194 | -126.33 | -47.936 | 0.365 | -0.003 |
| EPS
| -1.6 | -1.48 | -1.13 | 2.78 | 0.14 | -0.55 | -0.78 | -0.74 | -1.1 | -0.8 | -0.63 | -0.78 | -3.59 | 2.5 | -0.009 |
| EPS Diluted
| -1.6 | -1.48 | -1.13 | 2.78 | 0.14 | -0.55 | -0.76 | -0.72 | -1.1 | -0.8 | -0.63 | -0.78 | -3.59 | 2.5 | -0.009 |
| EBITDA
| -141.694 | -111.202 | -105.533 | -83.133 | 10.388 | -36.349 | -43.62 | -25.382 | -18.41 | -21.542 | -16.624 | -12.877 | -46.284 | 111.767 | -2.739 |
| EBITDA Ratio
| -1,089.954 | -203.667 | -232.452 | -328.589 | 30.463 | -23.182 | -60.083 | -27.529 | -24.32 | -41.992 | -37.526 | -128.77 | -42.935 | 0.398 | -0.024 |